An Allosteric Coagonist Model for Propofol Effects on α1β2γ2L γ-Aminobutyric Acid Type A Receptors
Open Access
- 1 January 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 116 (1) , 47-55
Abstract
Background: Propofol produces its major actions via γ-aminobutyric acid type A (GABA(A)) receptors. At low concentrations, propofol enhances agonist-stimulated GABA(A) receptor activity, and high propofol concentrations directly activate receptors. Etomidate produces similar effects, and there is convincing evidence that a single class of etomidate sites mediate both agonist modulation and direct GABA(A) receptor activation. It is unknown if the propofol binding site(s) on GABA(A) receptors that modulate agonist-induced activity also mediate direct activation. Methods: GABA(A) α1β2γ2L receptors were heterologously expressed in Xenopus oocytes and activity was quantified using voltage clamp electrophysiology. We tested whether propofol and etomidate display the same linkage between agonist modulation and direct activation of GABA(A) receptors by identifying equiefficacious drug solutions for direct activation. We then determined whether these drug solutions produce equal modulation of GABA-induced receptor activity. We also measured propofol-dependent direct activation and modulation of low GABA responses. Allosteric coagonist models similar to that established for etomidate, but with variable numbers of propofol sites, were fitted to combined data. Results: Solutions of 19 μM propofol and 10 μM etomidate were found to equally activate GABA(A) receptors. These two drug solutions also produced indistinguishable modulation of GABA-induced receptor activity. Combined electrophysiological data behaved in a manner consistent with allosteric coagonist models with more than one propofol site. The best fit was observed when the model assumed three equivalent propofol sites. Conclusions: Our results support the hypothesis that propofol, like etomidate, acts at GABA(A) receptor sites mediating both GABA modulation and direct activation.Keywords
This publication has 35 references indexed in Scilit:
- Clinical and Molecular Pharmacology of EtomidateAnesthesiology, 2011
- m-Azipropofol (AziPm) a Photoactive Analogue of the Intravenous General Anesthetic PropofolJournal of Medicinal Chemistry, 2010
- Mutational analysis of molecular requirements for the actions of general anaesthetics at the γ-aminobutyric acidA receptor subtype, α1β2γ2BMC Pharmacology, 2003
- 2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: A Derivative of the Stereoselective General Anesthetic Etomidate for Photolabeling Ligand-Gated Ion ChannelsJournal of Medicinal Chemistry, 2003
- General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA A receptor β3 subunitThe FASEB Journal, 2002
- Molecular determinants for the action of general anesthetics at recombinant α2β3γ2γ‐aminobutyric acidA receptorsJournal of Neurochemistry, 2001
- Methionine 286 in transmembrane domain 3 of the GABAA receptor β subunit controls a binding cavity for propofol and other alkylphenol general anestheticsNeuropharmacology, 2001
- General Anesthetic Potencies of a Series of Propofol Analogs Correlate with Potency for Potentiation of γ-Aminobutyric Acid (GABA) Current at the GABAA Receptor but Not with Lipid SolubilityThe Journal of Pharmacology and Experimental Therapeutics, 2001
- Propofol increases agonist efficacy at the GABAA receptorBrain Research, 2000
- Allosteric Activation Mechanism of the α1β2γ2 γ-Aminobutyric Acid Type A Receptor Revealed by Mutation of the Conserved M2 LeucineBiophysical Journal, 1999